European Medicines Agency's CHMP recommends approval for Iqirvo® and Kayfanda® for PBC and Alagille Syndrome in the second half of 2024.
The European Medicines Agency's CHMP has issued positive opinions for Ipsen's Iqirvo® (elafibranor) and Kayfanda® (odevixibat) for Primary Biliary Cholangitis (PBC) and Alagille Syndrome, respectively. These drugs, which target rare cholestatic liver diseases, are anticipated to go through final European Commission approval in the second half of 2024.
July 26, 2024
6 Articles